Aslan Pharmaceuticals Ltd Adr (ASLN) has released an update.
Aslan Pharmaceuticals Ltd Adr has reported promising interim results from a Phase 2 study for their drug, eblasakimab, in treating moderate-to-severe atopic dermatitis in patients previously treated with dupilumab. The study revealed significant improvements in skin clearance and itch relief compared to placebo, with a high percentage of patients achieving at least a 90% reduction in their Eczema Area Severity Index score. These results position eblasakimab as a potentially effective new therapy for patients who have not responded adequately to existing treatments.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.
